Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Am Heart J. 2018 Apr 4;201:164–167. doi: 10.1016/j.ahj.2018.03.019

Figure 1.

Figure 1.

Raw, unadjusted means ±1 SE at baseline and 3-month and 6-month follow-up visits for aliskiren (circles) and placebo (squares) for peak exercise VO2 by expired gas analysis. The number of evaluable patients is shown for the specific outcome at each visit (aliskiren versus placebo).